Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

8 results about "Monoclonal antibody" patented technology

Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages. Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one single monoclonal antibody to two epitopes.

Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity

InactiveUS20100015142A1Low toxicityDamage autoimmunityMetabolism disorderAntibody ingredientsDiseaseAutoimmune responses
The present invention provides methods of treating, preventing or ameliorating the symptoms of Latent Autoimmune Diabetes in Adults (LADA) and adult-onset type 1 diabetes through the use of anti-human CD3 antibodies. In particular, in invention provides methods of preventing or delaying insulin requirement in patients diagnosed with LADA. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor / alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-human CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
Owner:MACROGENICS INC

Chemical luminescence immune assay determination reagent kit for rubella virus IgM antibody and preparation method thereof

InactiveCN101368960ASensitive highStrong specificityChemiluminescene/bioluminescenceIgm antibodyEpidemiologic survey
The invention provides a test kit and a preparing method thereof for rubella IgG antibody detecting by integrating chemiluminescence immunoassay with capture method. The test kit is composed of positive and negative reference substance, a micro-perforated plate which is coated by antihuman IgM u link, neutralizing antigen, sample diluent, condensed washing liquid, alkaline phosphatase labeled monoclonal antibody, and chemiluminescence zymolyte. The preparing method of the test kit includes: 1) the positive and negative reference substance is prepared; 2) the micro-perforated plate is coated by the antihuman IgM u link; 3) the neutralizing antigen is prepared; 4) the sample diluent is prepared; 5) the condensed washing liquid is prepared; 6) the rubella monoclonal antibody is labeled by the alkaline phosphatase; 7) the chemiluminescence zymolyte is prepared; 8) all components above can be filled and packed through separate packing and finished product can be made after assembly. The invention has the advantages that the sensitivity is high and the specificity is strong, thereby providing serology detection, epidemiology investigation and clinical diagnose with a reliable scientific diagnosing evidence which is helpful in eugenics.
Owner:CHEMCLIN DIAGNOSTICS CO LTD

Cerebral Vasospasm Inhibitor

InactiveUS20090175878A1Few side-effectsImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsSubarachnoid spaceSide effect
An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.
Owner:UNIV OKAYAMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products